Tango Therapeutics
TNGX
About: Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Employees: 155
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1,265% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $97K
342% more capital invested
Capital invested by funds: $147M [Q1] → $652M (+$504M) [Q2]
75% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 7 (+3) [Q2]
40% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 30
18.16% more ownership
Funds ownership: 99.24% [Q1] → 117.4% (+18.16%) [Q2]
6% less funds holding
Funds holding: 122 [Q1] → 115 (-7) [Q2]
25% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 28
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Piper Sandler
Kelsey Goodwin
|
$11
|
Overweight
Initiated
|
19 Aug 2025 |
|
Guggenheim
Michael Schmidt
|
$10
|
Buy
Maintained
|
6 Aug 2025 |
Financial journalist opinion
